Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.06 billion. The enterprise value is $1.31 billion.
| Market Cap | 1.06B |
| Enterprise Value | 1.31B |
Important Dates
The next estimated earnings date is Wednesday, July 31, 2024, before market open.
| Earnings Date | Jul 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 46.55 million shares outstanding. The number of shares has increased by 13.59% in one year.
| Shares Outstanding | 46.55M |
| Shares Change (YoY) | +13.59% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 1.47% |
| Owned by Institutions (%) | 109.72% |
| Float | 46.06M |
Valuation Ratios
The trailing PE ratio is 15.68 and the forward PE ratio is 7.48. PCRX's PEG ratio is -3.83.
| PE Ratio | 15.68 |
| Forward PE | 7.48 |
| PS Ratio | 1.55 |
| Forward PS | 1.46 |
| PB Ratio | 1.19 |
| P/FCF Ratio | 6.11 |
| PEG Ratio | -3.83 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.91, with an EV/FCF ratio of 7.59.
| EV / Earnings | 18.65 |
| EV / Sales | 1.93 |
| EV / EBITDA | 6.91 |
| EV / EBIT | 11.35 |
| EV / FCF | 7.59 |
Financial Position
The company has a current ratio of 5.81, with a Debt / Equity ratio of 0.65.
| Current Ratio | 5.81 |
| Quick Ratio | 4.58 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 3.06 |
| Debt / FCF | 3.36 |
| Interest Coverage | 8.26 |
Financial Efficiency
Return on equity (ROE) is 8.30% and return on invested capital (ROIC) is 4.88%.
| Return on Equity (ROE) | 8.30% |
| Return on Assets (ROA) | 4.50% |
| Return on Capital (ROIC) | 4.88% |
| Revenue Per Employee | $957,520 |
| Profits Per Employee | $98,975 |
| Employee Count | 712 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.93 |
Taxes
In the past 12 months, PCRX has paid $31.35 million in taxes.
| Income Tax | 31.35M |
| Effective Tax Rate | 30.79% |
Stock Price Statistics
The stock price has decreased by -43.28% in the last 52 weeks. The beta is 0.87, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -43.28% |
| 50-Day Moving Average | 28.59 |
| 200-Day Moving Average | 29.61 |
| Relative Strength Index (RSI) | 25.66 |
| Average Volume (20 Days) | 1,263,494 |
Short Selling Information
The latest short interest is 6.36 million, so 13.67% of the outstanding shares have been sold short.
| Short Interest | 6.36M |
| Short Previous Month | 6.43M |
| Short % of Shares Out | 13.67% |
| Short % of Float | 13.81% |
| Short Ratio (days to cover) | 10.08 |
Income Statement
In the last 12 months, PCRX had revenue of $681.75 million and earned $70.47 million in profits. Earnings per share was $1.45.
| Revenue | 681.75M |
| Gross Profit | 498.69M |
| Operating Income | 103.98M |
| Pretax Income | 101.82M |
| Net Income | 70.47M |
| EBITDA | 190.25M |
| EBIT | 115.85M |
| Earnings Per Share (EPS) | $1.45 |
Balance Sheet
The company has $325.89 million in cash and $581.78 million in debt, giving a net cash position of -$255.89 million or -$5.50 per share.
| Cash & Cash Equivalents | 325.89M |
| Total Debt | 581.78M |
| Net Cash | -255.89M |
| Net Cash Per Share | -$5.50 |
| Equity (Book Value) | 892.16M |
| Book Value Per Share | 19.17 |
| Working Capital | 449.67M |
Cash Flow
In the last 12 months, operating cash flow was $184.62 million and capital expenditures -$11.43 million, giving a free cash flow of $173.19 million.
| Operating Cash Flow | 184.62M |
| Capital Expenditures | -11.43M |
| Free Cash Flow | 173.19M |
| FCF Per Share | $3.73 |
Margins
Gross margin is 73.15%, with operating and profit margins of 15.25% and 10.34%.
| Gross Margin | 73.15% |
| Operating Margin | 15.25% |
| Pretax Margin | 14.93% |
| Profit Margin | 10.34% |
| EBITDA Margin | 27.91% |
| EBIT Margin | 16.99% |
| FCF Margin | 25.40% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.59% |
| Shareholder Yield | -13.59% |
| Earnings Yield | 6.66% |
| FCF Yield | 16.36% |
Analyst Forecast
The average price target for PCRX is $47.40, which is 108.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $47.40 |
| Price Target Difference | 108.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 9.20% |
| EPS Growth Forecast (5Y) | 46.21% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 1.85 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.85 |
| Piotroski F-Score | 8 |